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Articular cartilage has a limited capacity to repair following injury. Early intervention is required to prevent
progression of focal traumatic chondral and osteochondral defects to advanced cartilage degeneration and
osteoarthritis. Novel cell-based tissue engineering techniques have been proposed with the goal of resurfacing
defects with bioengineered tissue that recapitulates the properties of hyaline cartilage and integrates into native
tissue. Transplantation of mesenchymal stem cells (MSCs) is a promising strategy given the high proliferative
capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. MSCs are
historically harvested through bone marrow aspiration, which does not require invasive surgical intervention or
cartilage extraction from other sites as required by other cell-based strategies. Biomaterial matrices are commonly
used in conjunction with MSCs to aid cell delivery and support chondrogenic differentiation, functional extracellular
matrix formation and three-dimensional tissue development. A number of specific transplantation protocols have
successfully resurfaced articular cartilage in animals and humans to date. In the clinical literature, MSC-seeded
scaffolds have filled a majority of defects with integrated hyaline-like cartilage repair tissue based on arthroscopic,
histologic and imaging assessment. Positive functional outcomes have been reported at 12 to 48 months
post-implantation, but future work is required to assess long-term outcomes with respect to other treatment
modalities. Despite relatively positive outcomes, further investigation is required to establish a consensus on
techniques for treatment of chondral and osteochondral defects with respect to cell source, isolation and expansion,
implantation density, in vitro precultivation, and scaffold composition. This will allow for further optimization of MSC
proliferation, chondrogenic differentiation, bioengineered cartilage integration, and clinical outcome.Introduction
Articular cartilage (AC) injury following joint trauma is
a major risk factor for the development of osteoarthritis
(OA), a condition that results in significant patient mor-
bidity and substantial cost to healthcare systems [1-4]. Ap-
proximately 10 to 25% of the population suffers from OA,
with increased prevalence noted in older age groups [4,5].
OA is irreversible and eventually requires joint replace-
ment for alleviation of pain and restoration of function as
it progresses to end-stage disease. Due to the limited cap-
acity of AC to repair, early intervention is required to* Correspondence: adesida@ualberta.ca
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reproduction in any medium, provided the orprevent progression to OA [6]. Effective management
options are limited at present, resulting in a drive to de-
velop novel tissue engineering techniques to resurface
AC defects [7].
Current treatment modalities aim to restore AC through
primary repair, stimulation of adjacent tissue and graft im-
plantation. Primary repair involves rigid fixation of osteo-
chondral fractures in an acute setting [8]. Microfracture
and subchondral drilling breach subchondral bone to
allow migration of cells and chemical mediators into de-
fects [6]. Although this leads to defect filling with repair
tissue that is predominantly fibrocartilage [9], reasonable
results can be obtained in the short- to intermediate-term
with proper rehabilitation [10,11].
Osteochondral autologous transplantation and mosaic-
plasty are performed through transplanting one or moreLtd. The licensee has exclusive rights to distribute this article, in any medium, for
ime, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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surfaces [12]. Although intermediate-term outcomes have
been positive, outcomes are variable over longer periods of
time [12,13]. Furthermore, donor site morbidity is the
major downside of this technique [13]. Allogeneic trans-
plantation is an alternative strategy that allows for re-
surfacing of large osteochondral defects. Fresh allografts
stored at 4°C provide good clinical outcomes [14], but
are logistically difficult given the need for donor-recipient
size matching, testing for infectious diseases and implant-
ation within a short time frame to ensure chondrocyte
viability [15]. Freezing of tissue allows for longer-term
storage, but outcomes deteriorate quickly following im-
plantation of frozen allografts [16]. However, cryopreser-
vation could be a suitable alternative in the future given
the establishment of vitrification protocols that have
yielded promising results [17]. Bioengineered scaffolds
implanted alone, or in conjunction with marrow stimu-
lation in autologous matrix-induced chondrogenesis, ef-
fectively fill joint defects and improve function, but it is
currently unclear whether the resulting repair tissue re-
capitulates the properties of AC [18,19].
Autologous chondrocyte implantation (ACI) involves
chondrocyte isolation from cartilage in non-weight bearing
areas, expansion ex vivo and re-implantation into the car-
tilage defect covered by a periosteal graft [20]. In matrix-
associated ACI (MACI), chondrocytes are implanted on
three-dimensional porous scaffolds that facilitate three-
dimensional repair tissue formation and defect filling [11].
Positive outcomes have been reported at 7 to 13 years for
knee lesions [11,20], and 2 to 5 years for ankle lesions
[21,22]. However, both techniques require two invasive
surgical procedures [20]. Low chondrocyte yield, loss of
capacity to make hyaline cartilage-like extracellular matrix
(ECM) due to chondrocyte de-differentiation, and chon-
drocyte senescence are concerns [23-25].
Transplantation of mesenchymal stem cells (MSCs) is
a cell-based strategy that has the potential to resurface
AC defects while avoiding the downsides of ACI/MACI.
MSCs have an enhanced proliferative capacity and can
be reproducibly differentiated into chondrocytes [26]. Cell
harvesting does not require an invasive procedure or
wounding of AC at another site.
The aim of this article is to provide a comprehensive
review of MSC-based cartilage regeneration from bench
to bedside and a discussion of the current technical con-
siderations in MSC transplantation for treatment of trau-
matic, focal chondral and osteochondral defects.
Methods
A comprehensive literature search was performed of
MEDLINE, EMBASE and Web of Science databases to
identify English articles published between 1994 and 2014
using various combinations of the following keywords:mesenchymal stem cell, stromal cell, bone marrow cell,
cartilage, chondrogenesis, transplantation, in vitro, ex vivo,
monolayer, cell aggregate, pellet, micromass, hydrogel, ex-
plant, in vivo, animal, rat, rabbit, dog, sheep, horse, pig,
goat, murine, leporine, canine, ovine, equine, porcine,
caprine, and human. Search steps performed within each
database specifically for in vitro, in vivo animal and clinical
literature are detailed in Additional file 1. Compilation of
database outputs produced 6,137, 2,603 and 2,528 publica-
tions, respectively, for these searches. In vivo articles were
then screened and included if they met the following cri-
teria: (1) publication in English between 1994 and 2014;
(2) clinical design with Oxford Centre for Evidence-Based
Medicine 2011 level of evidence I to IV [27] or controlled
animal design; and (3) assessment of MSC-based treat-
ment of in vivo traumatic (natural or simulated), focal
chondral or osteochondral defects. Relevant articles found
within reference lists and within the journal Cartilage
were also screened and considered for inclusion. This
process yielded 36 pre-clinical in vivo animal studies,
including 21 small animal and 15 large animal studies,
and 15 clinical studies (Figure 1). Only key in vitro arti-
cles were included in our review as several hundred
relevant articles were found within our initial search.
Mesenchymal stem cells
MSCs are spindle-shaped cells capable of rapid prolifera-
tion and self-renewal contained within a number of tissues,
including bone marrow, synovial tissue, blood, adipose tis-
sue, and periosteum [26,28,29]. Their multi-lineage poten-
tial allows for differentiation into a variety of cell types in
order to create and repair mesenchymal tissues. MSCs
have been differentiated into chondrogenic, osteogenic,
and adipogenic pathways [26]. Mediators capable of pro-
moting MSC chondrogenesis, such as transforming growth
factor-beta (TGF-β) and dexamethasone, have been eluci-
dated using simplified in vitro models [30].
Mesenchymal stem cell-based cartilage
regeneration from bench to bedside
In vitro studies
MSC chondrogenesis can be induced within simple in vitro
models consisting of cell monolayers or cell aggregates,
pellets, micromasses, or transwell cultures containing mul-
tiple layers of cells and ECM [26,31-33]. High-density ag-
gregation was achieved through the use of centrifugation
and situates cells in a three-dimensional environment that
fosters cellular interaction, mimicking cell condensation of
mesenchymal cells during embryonic cartilage develop-
ment and chondrogenic ECM formation [26,30]. Alter-
natively, various biomaterials have been used as matrices
on which MSCs are differentiated. MSCs embedded
within collagen, agarose, alginate, chitosan and hyalur-
onic acid (HA) gels form aggregates of tissue that
Database Search 
MEDLINE, EMBASE and Web of Science (July 4, 2014) 
Keywords: mesenchymal stem cell, stromal cell, bone marrow 
cell, cartilage, chondrogenesis, transplantation, in vitro, ex vivo, 
monolayer, cell aggregate, pellet, micromass, hydrogel, in vivo, 
animal, rat, rabbit, dog, sheep, horse, pig, goat, murine, leporine, 






Inclusion criteria: (1) publication in English language between 
1994-2014, (2) clinical design with OCEBM 2011 Level of 
Evidence I-IV, or controlled animal design, (3) assessment of 
MSC-based treatment of in vivo traumatic (natural or simulated) 





2571 articles excluded 2518 articles excluded 
4 articles added 5 articles added 
Figure 1 Search strategy and selection of pre-clinical and clinical literature. MSC, mesenchymal stem cell; OCEBM, Oxford Centre for
Evidence-Based Medicine.
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MSC-seeded porous scaffolds composed of collagen, HA,
silk, decellularized cartilage ECM, polyglycolic acid (PGA),
polylactic acid (PLA) and polylacticglycolic acid (PLGA)
create tissue that histologically resembles hyaline cartil-
age [39-43].Ex vivo studies
Chondral and osteochondral explant models allow for car-
tilage repair tissue formation to be assessed within simu-
lated defects in controlled in vitro environments. Porcine
MSCs embedded in agarose gel implanted within chondral
explants showed an abundance of type II collagen and gly-
cosaminoglycan (GAG) matrix after 6 weeks of culture
[35]. Similarly, human MSCs embedded in alginate gel and
implanted within osteochondral explants for 4 weeks had
collagen II gene expression and GAG production consist-
ent with hyaline cartilage [34]. MSC-seeded gels displayed
minimal integration with surrounding explant cartilage
after 6 weeks of culture [35]. This may be due, in part, to
the absence of sufficient remodeling time or in vivo factors,such as mechanical stimulation, required for integration to
occur [44].In vivo animal studies
Animal models have provided pre-clinical in vivo assess-
ment of MSCs in the treatment of AC defects. Starting
with the work of Wakitani and colleagues in 1994 [7],
MSC-based techniques have yielded positive outcomes
in regenerating AC in several small animal studies involv-
ing rabbits [45-62] and rats [63,64]. Various MSC injection
and transplantation protocols have been used to treat sim-
ulated, focal chondral and osteochondral defects in large
animals such as sheep, goats, pigs, and horses [38,65-78].
These large animal studies are summarized in Table 1.
Intra-articular injection of MSCs into rabbit knees con-
taining femoral trochlea osteochondral defects led to re-
surfacing with fibrous tissue that failed to remodel into
hyaline cartilage over 24 weeks [52]. In contrast, MSCs
implanted directly into the defect site produced cartilage-
like tissue that remodeled with time to produce both car-
tilage and bone components similar to surrounding native
















Implantation of isolated BM-derived
MSCs seeded on a TCP scaffold;
compared to cell-free scaffolds and
empty defects
6 months Macroscopic: smooth, integrated tissue in
MSC group. Histologic: proteoglycan and
type II collagen consistent with hyaline
cartilage in MSC group, compared with
fibrocartilage in cell-free group; subchon-
dral osseous regeneration. Biochemical:









Implantation of isolated BM-derived
MSCs suspended in alginate and
seeded on a PLA scaffold; preculti-
vated for 3 wk; compared to cell-free
scaffolds
1.5 months Macroscopic: improved coverage of
defects in MSC group. Histologic: mixture
of hyaline and fibrocartilage integrated
with surrounding tissue; higher quality
tissue in MSC group compared with cell-
free group; no mineralization noted within
osseous defects. Mechanical: lower resist-
ance to compression than native cartilage
Ando et al.
(2007) [67]




Implantation of isolated, allogeneic
synovial tissue MSCs derived from
piglets and cultured in a three-
dimensional scaffold-free TEC; com-
pared to empty defects
6 months Macroscopic: greater defect coverage in
TEC group; subchondral erosion in the
empty defects. Histologic: smooth,
integrated tissue containing proteoglycans
and type II collagen in the TEC group;
empty defects showed signs of OA; higher
ICRS scores in the TEC group. Mechanical:










Injection of isolated BM-derived
MSCs with HA (Synvisc) followed by
HA weekly × 2 wk; compared to HA
alone
3 months Macroscopic: greater defect coverage in
the MSC + HA group. Histologic: hyaline-
like cartilage noted in MSC + HA group;
minimal defect filling in HA group; im-








Injection of BMDC collection with
HA (Hyalgan) weekly for 3 wk
starting 1 wk after subchondral
drilling; compared to drilling with or
without HA
6 months Macroscopic: greater defect coverage in
the BMDC + HA group. Histologic: HA
group had some proteoglycans and type II
collagen mixed with type I collagen;
BMDC + HA group had superior
proteoglycan and type II collagen content;
cell morphology was improved in the








Implantation of isolated BM-derived
MSCs in type I (rat) collagen gel ei-
ther immediately following seeding
or after 2 wk of precultivation
6 months Macroscopic: precultivation group
produced more homogenous hyaline-like
cartilage. Histologic: significantly better
O’Driscoll and ICRS scores in the
precultivation group compared with non-
precultivated group, specifically with re-
spect to surface features, integration, cell
distribution, and mineralization. Mechan-










Implantation of isolated synovial
tissue MSCs derived from piglets and
cultured in a three-dimensional
scaffold-free TEC; compared to
empty defects
6 months Macroscopic: greater defect coverage in
TEC group. Histologic: good integration of
tissue that stained well for proteoglycans
in the TEC group versus signs of OA in
empty defects; higher ICRS scores in the
TEC group. Mechanical: similar properties








Implantation of BM cells in fibrin
glue seeded on a PGA scaffold;
secured to subchondral bone by
PLGA darts; compared to cell-free
scaffolds
3 months Macroscopic: BM-seeded scaffolds had im-
proved regeneration compared with cell-
free scaffolds. Histologic: variation noted
with fibrous tissue in some and hyaline-
like cartilage in other BM cell-seeded scaf-
folds; O’Driscoll score was similar between
cell-free and cell-seeded scaffolds
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Implantation of isolated BM-derived
MSCs in type I (rat) collagen gel im-
planted either immediately following
seeding or after 2 wk of precultiva-
tion; compared to MACI
12 months Macroscopic/histologic: significantly better
O’Driscoll and ICRS scores with
precultivated MSCs compared with both
non-precultivated MSCs and MACI, specif-
ically with respect to surface quality,
matrix quality and integration; type II colla-
gen content was superior in precultivated
group. MRI: precultivated MSCs were simi-
lar to MACI but significantly better than





10 horses Medial femoral condyle
chondral defects
(1 cm2)
Injection of isolated BM-derived
MSCs with HA (Hyvisc) into the knee
joint 1 month after MFX; compared
to cell-free HA injection and MFX
12 months Macroscopic: greater repair tissue area
with MSCs, but no difference in volume.
Histologic: no difference in surface,
structure, integration, cellular architecture,
and subchondral regeneration;
contradictory proteoglycan and aggrecan
staining. Biochemical: equivalent GAG.
Mechanical: tissue derived from MSCs was
firmer. MRI: no difference
Ando et al.
(2012) [74]




Implantation of isolated, allogeneic
synovial MSCs and cultured in a
three-dimensional scaffold-free TEC;
compared to empty defects
6 months Histologic: tissue containing proteoglycans
in the TEC group; empty defects were
partially covered with fibrous tissue and
showed signs of OA; higher O’Driscoll
scores in the TEC group. Mechanical:










Implantation of BMDCs or isolated,
expanded BM-derived MSCs in type
II collagen (porcine) hydrogel; com-
pared to cell-free gels
2 months Macroscopic: good defect filling with both
MSCs and BMDCs; irregularity with cell-
free gels. Histologic: hyaline-like cartilage
with both MSCs and BMDCs; O’Driscoll
score was greater in the MSC group at 4
wk, but equivalent between the BMDC
and MSC groups at 8 wk
Bekkers et al.
(2013) [76]




Implantation of chondrons and BM-
derived MSCs suspended in fibrin
glue; compared to MFX
6 months Macroscopic: improved defect filling with
MSC + chondrons in comparison to MFX.
Histologic: O’Driscoll score was
significantly higher in the MSC + chondron
group. Biochemical: GAG content and
GAG/DNA in the repair tissue was greater









Magnetic accumulation of injected
ferumoxide labeled MSCs; compared
to gravity-focused MSCs
3 months Arthroscopic: improved smoothness and
integration with magnetic accumulation.
Histologic: superior integration and type II
collagen content with magnetic








Injection of isolated BM-derived
MSCs weekly (×3 wk) starting 2 wk
after subchondral drilling; compared
to drilling alone
6 months Macroscopic: smooth, integrated tissue
with MSCs versus partial, irregular filling
with drilling alone. Histologic: O’Driscoll
score was significantly higher in the MSC
group; improved proteoglycan and type II
collagen content with MSCs. Biochemical:
higher GAG quantity with MSCs
BM, bone marrow; BMDC, bone marrow-derived cell; GAG, glycosaminoglycan; HA, hyaluronic acid; ICRS, International Cartilage Repair Society; MACI,
matrix-associated autologous chondrocyte implantation; MFX, microfracture; MOCART, Magnetic Resonance Observation of Cartilage Repair Tissue; MRI, magnetic
resonance imaging; MSC, mesenchymal stem cell; OA, osteoarthritis; PGA, polyglycolic acid; PLA, polylactic acid; PLGA, polylactide co-glycolide; TCP, tricalcium
phosphate; TEC, tissue-engineered construct; wk, week(s).
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conjunction with HA into porcine knees with partial-
thickness chondral defects led to good defect coveragewith hyaline-like cartilage at 12 weeks post-injection
[68]. HA alone produced minimal defect filling in this
time frame.
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ation with subchondral drilling or microfracture [69,73,78].
Serial MSC injections performed weekly for 3 weeks after
subchondral drilling for treatment of simulated chondral
defects within the distal femur of goats produced inte-
grated repair tissue consistent with hyaline cartilage after
6 months [78]. In a similar model, Saw and colleagues [69]
used bone marrow aspirate cell collections injected weekly
with HA. They found improved content of proteoglycan
and type II collagen within femoral trochlea chondral de-
fects that received cell injection in comparison to those
that received only HA. In contrast to these findings, McIl-
wraith and colleagues [73] found no difference between
HA and an HA-MSC combination in several histologic pa-
rameters, magnetic resonance imaging (MRI) evaluation,
and GAG quantity at 1 year in horses that received an in-
jection and microfracture. Possible reasons for inconsistent
outcomes include variation in the number of injections,
length of follow-up and species.
One potential drawback of intra-articular injection in-
volves cell dispersion, associated lack of focus of injected
contents into a defect site, and the potential for an insuf-
ficient amount of seeded cells required for regeneration.
The use of magnetic labeling of cells and an external mag-
net has been proposed as a minimally invasive method to
deliver injected MSCs to defects. In mini-pig knees,
ferumoxide-labeled MSCs were directed over patella
chondral lesions by magnet for 10 minutes following in-
jection and produced superior arthroscopic and histo-
logic scores to an injection directed by gravity [77].
Various constructs for implantation have been proposed
in the pre-clinical literature. A scaffold-free, three-
dimensional tissue-engineered construct (TEC) derived
from monolayers containing differentiated MSCs has
been investigated [70,74]. Over 6 months, TECs implanted
within porcine femoral condyle chondral defects created
repair tissue with a superficial fibrous layer and deep AC-
like layer [70].
Transplantation of MSC-seeded matrices composed of
collagen, PLA, PGA, PLGA, polycaprolactone, fibrin,
chitosan, alginate, silk, demineralized bone matrix, and
tricalcium phosphate was successfully performed in sev-
eral other small and large animal studies [7,45-49,51,54,
56,57,59-61,63,71,79]. Defect resurfacing with hyaline-
like cartilage tissue was reported in the majority of cases
at 4 to 24 weeks post-implantation with more inte-
grated, mature tissue found at later time points. Some
groups also noted the presence of bone regeneration
within the osseous component of osteochondral defects
[47,48,57,61,65].
Implantation of matrices seeded with MSCs that were
precultivated in vitro for 2 to 3 weeks prior to implant-
ation is an alternative protocol that has been assessed in
three other studies [38,66,72]. Zscharnack and colleagues[38] showed that precultivated MSC-seeded collagen gels
implanted within sheep osteochondral defects produced
superior repair tissue to non-precultivated MSC-seeded
gels based on International Cartilage Repair Society (ICRS)
histologic scoring at 6 months post-implantation. Mar-
quass and colleagues [72] had similar findings after 1 year
and also showed that precultivated MSCs had better histo-
logic outcomes than precultivated chondrocytes (MACI).
Bone marrow nucleated cells - often described as bone
marrow-derived cells (BMDCs) in the literature [80,81] -
were seeded on collagen gels and compared with isolated,
expanded MSCs by Zhang and colleagues [75]. After
2 months, both cell types produced histologically and
macroscopically equivalent hyaline-like cartilage repair tis-
sue within porcine femoral trochlea chondral defects.
Co-transplantation of chondrons and MSCs suspended
within fibrin glue into goat femoral condyle chondral de-
fects was assessed in another study [76]. This technique
showed superior defect filling, O’Driscoll histologic scoring
and biochemical GAG quantity in comparison to micro-
fracture. However, co-transplantation was not compared
with MSC or chondrocyte transplantation alone.
Animal studies have yielded positive pre-clinical re-
sults that have provided support and direction for MSC-
based therapies in humans. Specific techniques such as
MSC injection, and transplantation of both isolated MSCs
and BMDCs have been taken into the clinical realm.
Other techniques such as scaffold-free TEC, magnetically
guided MSC injection, co-transplantation, and MSC pre-
cultivation have only been reported in the animal litera-
ture to date.
Clinical studies
A growing body of clinical evidence supports MSC im-
plantation as an effective treatment for traumatic AC in-
jury (Table 2). Cells derived from autologous bone marrow
aspirates from the iliac crest have been used for treatment
of focal, traumatic chondral and osteochondral defects of
the femoral condyle [81-87], femoral trochlea [84,88,89],
talus [80,90,91], tibial plateau [89], and patella [84,88,89].
Other studies have addressed the use of this technique in
managing other defect types, such as osteochondral lesions
arising from osteochondritis dissecans [92,93], septic arth-
ritis [94] and unicompartmental OA [95].
Following aspiration, MSCs were isolated and ex-
panded within the laboratory for 2 to 3 weeks and im-
planted alone [84,93] or in association with biomaterial
matrices [82,83,85,88]. Alternatively, in other studies,
BMDCs - also described as bone marrow concentrate
[86,87] or bone marrow aspirate concentrate [89] - were
separated using centrifugation systems [80,81,86,87,89-91].
Presumably, these collections contained a variety of cell
types from the bone marrow space, some of which were
MSCs. BMDCs were immediately implanted in conjunction
Table 2 Clinical studies assessing mesenchymal stem cell-based treatment of traumatic chondral and osteochondral defects
Scientific
publication







1 M (age 31 y) 1 medial femoral condyle chondral
defect (6.0 cm2) from trauma
Implantation of isolated BM-derived
MSCs within porcine type I collagen
gel on a collagen scaffold; covered
by a periosteal flap
12 months Arthroscopic: firm, smooth repair
tissue. Histologic: hyaline-like cartil-
age covered superficially by fibrous
tissue. MRI: focal chondral and sub-
chondral irregularities. Clinical: return





3: 2 M, 1 F (age
32–45 y)
5 femoral trochlea (0.7-4.2 cm2) and
4 patella chondral defects (1.0-
1.7 cm2); defects in 2/3 participants
from trauma
Implantation of isolated BM-derived
MSCs within bovine type I collagen
gel on a porcine collagen scaffold;
covered by a periosteal flap or syno-
vium; adjunctive subchondral drilling
18 months Arthroscopic: firm, smooth tissue.
Histologic: atypical cartilage. MRI:
complete coverage of defects but
quality unclear. Clinical:
improvement of symptoms and





48: 27 M, 21 F
(mean age 28.5 ±
9.5 y)
48 talar dome osteochondral defects
(2.07 ± 0.48 cm2); 35 from trauma;
previous MFX, debridement or ACI in
15
Implantation of BMDCs suspended
within collagen/platelet paste or
seeded on HA (Hyaff-11) scaffold
24-35 months Arthroscopic: smooth tissue in some,
hypertrophic in others; all integrated
with firmness of native cartilage.
Histologic: mixed with some hyaline
quality. MRI: newly formed tissue in
all lesions. Clinical: improvement in
AOFAS scores with time and return
to sports with no difference
between scaffold types; worse
outcomes with previous surgery




20: 12 M, 8 F
(mean age 28.5 ±
9.5 y)
16 medial femoral condyle and 6
lateral condyle osteochondral
defects (no area provided); 18
traumatic and 2 OCD defects
Implantation of BMDCs seeded on a
HA (Hyalofast) scaffold
supplemented with platelet-rich fi-
brin; adjunctive meniscus repair or
debridement, ACL-R, or HTO
29 ± 4.1 months Histologic: collagen II noted
throughout repair tissue with focal
proteoglycan content consistent
with hyaline-like cartilage. MRI: vari-
able signal intensity that correlated
with KOOS score. Clinical: improve-








81: 47 M, 34 F
(mean age 30 ± 8
y); 25 BMDC; 10
ACI; 46 MACI
81 talar dome osteochondral defects
(>1.5 cm2) from trauma
Implantation of BMDCs seeded on a




Arthroscopic: good defect coverage.
Histologic: hyaline-like cartilage
noted. MRI: complete integration in
76% and homogenous tissue in 82%
of all cases with hypertrophy in 3
BMDC and 2 ACI patients. Clinical:
improvement in AOFAS scores after
surgery with no difference between
BMDC-scaffold implants, ACI and
MACI; lower overall cost for BMDC





















5: 4 M, 1 F (mean
age 25.4 y)
5 femoral condyle chondral defects
(3–12 cm2); 2 traumatic, and 3 OCD
defects (1 OA from neglected OCD)
Implantation of isolated BM-derived
MSCs within platelet-rich fibrin glue;
covered by a periosteal flap
12 months Arthroscopic: smooth tissue. MRI:
complete defect filling with good
congruity in 3/5 patients. Clinical:
improvement in Lysholm and RHSSK
scores with return to sports; worse








72: 38 M, 34 F
(mean age 44.0 ±
11.4 y), 36 MSCs;
36 ACI
13 patella, 4 femoral trochlea, 12
femoral condyle, and 7 multiple
knee chondral defects (4.6 ± 3.5 cm2);
14 traumatic, 20 OA and 2 other
defects
Implantation of isolated BM-derived
MSCs; covered by a periosteal flap;
adjunctive partial meniscectomy, pa-
tellar realignment, ACL-R, or HTO
24 months Arthroscopic: smooth tissue in most
cases. Histologic: aggrecan and
collagen II content consistent with
hyaline cartilage. Clinical: greater
improvement in SF-36 Physical Role
Functioning in MSCs versus chondro-
cytes; equivalent IKDC, Tegner and
Lysholm score improvement follow-
ing both MSC and chondrocyte
transplantation; superior outcomes in
males versus females




15: 10 M, 5 F
(mean age 48 y,
range 32–58 y)
7 patella, 6 femoral trochlea, 4
medial tibial plateau, 6 medial
femoral condyle, and 1 lateral
condyle chondral defects (9.2 ±
6.3 cm2); all defects from trauma; 6
patients had multiple defects
Implantation of BMDCs mixed with
batroxobin (Plateltex Act) to produce
a clot; covered by a type I/III
collagen matrix (Chondro-Gide);
adjunctive ACL-R, HTO, patellar
realignment
24-38 months Arthroscopic: smooth, integrated
tissue in all cases; no hypertrophy.
Histologic: variability with properties
of hyaline and fibrocartilage. MRI:
complete defect filling in 80%,
integration in 93%, and no
hypertrophy in all patients. Clinical:
improvement in all scores (VAS,
KOOS, Tegner, Marx, IKDC and
Lysholm) following surgery; patients
with single lesions and smaller
lesions had better outcomes
Kasemkijwa-ttana
et al. (2011) [85]
Case series: level
IV evidence
2 M (age 24–25 y) 2 lateral femoral condyle chondral
(2.2-2.5 cm2)
Implantation of isolated BM-derived
MSCs seeded on a type I collagen
scaffold supplemented with fibrin
glue; covered by a periosteal flap;
adjunctive ACL-R, meniscal repair
30-31 months Arthroscopic: good defect fill,
integration and firmness. Clinical:
significant improvement in IKDC
score and KOOS post-operatively




5: 1 M, 4 F (mean
age 39.4 y, range
19–52 y)
3 focal defects: 1 lateral femoral
condyle (2 cm2), 1 patella (8.8 cm2),
1 femoral trochlea (0.5 cm2); 2 OA
defects
Injection of peripheral blood-derived
MSCs with HA weekly (×5) starting 1
wk after subchondral drilling; ad-
junctive HTO or lateral patellar re-
lease; pre-injection GCSF
10-26 months Arthroscopic: good filling in focal
defects; range from devoid areas to
smooth repair tissue in OA defects.
Histologic: intense proteoglycan
staining; type I collagen in superficial
area with predominance to type II
collagen in deep area; chondrocytes





1 M (age 37 y) 1 medial femoral condyle chondral
defect (3 cm2) from trauma
Implantation of BMDCs within fibrin
glue (Tisseel) and coverage with a
collagen membrane (MeRG) after
arthroscopic MFX (CMBMC)
24 months MRI: good defect filling with tissue
that was isointense relative to native
cartilage; no signs of bone edema.
















Table 2 Clinical studies assessing mesenchymal stem cell-based treatment of traumatic chondral and osteochondral defects (Continued)




9: 5 M, 4 F (mean
age 48 ± 9 y)
6 medial femoral condyle and 3
lateral condyle chondral defects (2.6
± 0.5 cm2); previous meniscectomy,
debridement or ACL-R
Implantation of BMDCs within fibrin
glue and coverage with a PGA-HA
membrane (Chondro-tissue) after
arthroscopic MFX (CMBMC); adjunct-
ive meniscectomy, osteochondral fix-
ation, or trochlea resurfacing
22 ± 2 months Arthroscopic: 1 normal, 3 nearly
normal and 1 abnormal on ICRS CRA.
Histologic: hyaline-like cartilage re-
pair tissue. MRI: complete defect fill-
ing in all; mild subchondral
irregularities in all; hypertrophy in 1
patient. Clinical: improvement in
IKDC and Lysholm scores compared
with pre-operative scores; no change






49: 27 M, 22 F
(mean age 28.1 ±
9.5 y)
49 talar dome osteochondral defects
(2.2 ± 1.2 cm2); 36 traumatic defects
with unknown etiology in others;
previous debridement, MFX, ACI, or
BMDCs in 17
Implantation of BMDCs within
collagen/platelet paste or seeded on
HA (Hyaff-11) scaffold supplemented
with platelet gel
48 months MRI: complete defect filling in 45%,
hypertrophy in 45%, integration in
65%, subchondral disruption in 65%
of cases; 78% of repair area had
hyaline quality. Clinical: improvement
in AOFAS scores - maximal value at
24 months; decreased at 36–48
months; decreased AOFAS associated
with fibrocartilage quality; return to
pre-injury sports in 78%




49: 17 M, 32 F
(mean age 38 ± 7
y); 25 MSC + HA;
24 HA
49 chondral defects of the knee
(57% patella, 29% trochlea, 12%
femoral condyle, and 8% tibial
plateau)
Injection of peripheral blood-derived
MSCs and HA weekly (×5) starting 1
wk after subchondral drilling and
then weekly (×3) at 6 months; pre-
injection GCSF
24 months Arthroscopic: smooth defect filling.
Histologic: ICRS II score was
significantly better in MSC + HA
group. MRI: improved cartilage
morphology, defect filling and
integration in MSC + HA group.
Clinical: improvement in IKDC scores
with no difference between MSC +
HA and HA
ACI, autologous chondrocyte implantation; ACL-R, anterior cruciate ligament reconstruction; AOFAS, American Orthopaedic Foot and Ankle Society; BM, bone marrow; BMDC, bone marrow-derived cell; CMBMC, cov-
ered microfracture and bone marrow concentrate; CRA, Cartilage Repair Assessment (arthroscopy); F, female; GCSF, granulocyte colony stimulating factor; HA, hyaluronic acid; HTO, high tibial osteotomy; ICRS, Inter-
national Cartilage Repair Society; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; M, male; MACI, matrix-associated autologous chondrocyte implantation;
MFX, microfracture; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; OA, osteoarthritis; OCD, osteochondral dissecans; PGA-HA, polyglycolic acid-hyaluronic acid; RCT, randomized controlled trial; RHSSK,
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as the aspiration. Matrices used in these studies in-
cluded platelet-rich fibrin gel [80,81,83,89,90], fibrin
glue [86,87], collagen gel and paste [80,82,88,90,91], and
scaffolds composed of collagen [82,85,86,88,89], HA
[80,81,90-92], and PGA-HA [87]. In most cases, MSCs or
BMDCs were seeded onto scaffold or gel matrices for im-
plantation. Combinations of scaffolds and cell-containing
gels or glue were commonly described [80-82,86-88,90-
92,96]. Some protocols involved the implantation of cells
within gel followed by coverage with biomaterial mem-
branes [86,87,89]. Cell-matrix constructs were implanted
on the same day of scaffold seeding [80,81,90-92,96] or
following a few days of in vitro culture in an attempt to
promote cell adherence to scaffolds prior to implantation
[82,88]. Some groups used fibrin glue [84] and overlying
periosteal flaps [82-84,88,93,95] or synovium [88] to
stabilize implanted constructs.
Based on the available early evidence, implantation of
MSCs or BMDC collections containing MSCs appears to
be a successful treatment for focal traumatic chondral
and osteochondral defects (Table 3). Clinical outcomes
improved with time over 24 months following implant-
ation in the majority of patients with focal chondral and
osteochondral lesions of the knee [81,84-89] and ankle
[80,90,91]. These positive outcomes contrast with those
from patients with more advanced degenerative disease. In
one study focusing on the management of unicompart-
mental OA of the knee, outcomes were equivalent between
the MSC transplantation group and cell-free control group
in 24 patients who underwent concomitant high tibial oste-
otomy [95]. Furthermore, one participant with OA in an-
other case series had worse clinical scores post-operatively
than others with focal defects [83].
To date, there is a relative paucity of literature assessing
clinical outcomes beyond 24 months in patients treated
with MSC or BMDC transplantation for focal AC defects.
One group reported outcomes up to 48 months and noted
a slight decrease in American Orthopaedic Foot and
Ankle Society (AOFAS) scores at both 36 and 48 months
compared with 24 months post-implantation [91]. Longer-
term evidence is now available from Wakitani and col-
leagues [97] supporting the safety of MSC transplantation
up to 137 months post-surgery, although other outcomes
were not assessed.
MRI and arthroscopy have shown that repair tissue
derived from MSC and BMDC transplantation contains
hyaline-like cartilage and integrates within surrounding
native tissue within 24 months of implantation [80,81,
85-87,91] (Table 2). Cartilage quality correlated with
clinical outcomes [81,91] as did implant-defect congru-
ity and the amount of defect filling [83]. In some cases,
hypertrophic cartilage has been noted on arthroscopy,
but healthy repair tissue was found upon arthroscopicdebridement of this tissue [80]. Lack of complete filling
and non-congruent resurfacing of defects have been re-
ported in a minority of cases [83]. In osteochondral le-
sions, subchondral bone appears to require longer periods
of time than cartilage for remodeling. Giannini and col-
leagues [91] found abnormal subchondral structure and
separated osteochondral interfaces on MRI at 24 months
following treatment of osteochondral lesions of the talus.
Histological analysis of repair tissue biopsies has been
consistent with MRI and arthroscopic findings [80-82,
86,87,89] (Table 2). A number of groups have reported
intense proteoglycan staining surrounding differentiated
chondrocytes [80,81,87,89]. Furthermore, repair tissue
often contained a moderate to large amount of collagen
II with lesser amounts of collagen I on immunohistochem-
istry that supported the presence of hyaline-like cartilage
phenotype [80,82,84,89]. Fibrocartilage or mixed repair
tissue has also been described, but in a relatively smaller
number of patients [82,87,88]. Periosteal flaps and sub-
chondral drilling were used in these studies and are poten-
tial contributing factors.
Two clinical studies have compared MSC/BMDC trans-
plantation to chondrocyte transplantation (ACI/MACI)
[84,90]. Similar positive outcomes were noted on most
clinical scales. Better physical role functioning on the
ICRS Package Short Form-36 (SF-36) scale was noted
with MSCs relative to chondrocytes [84]. MRI, arthro-
scopic and histologic findings indicated that both proce-
dures were capable of resurfacing defects with hyaline-like
cartilage repair tissue that integrated into surrounding
cartilage [84,90].
Although implantation of MSC-based constructs has
been the focus of clinical literature to date, one group
has reported outcomes following intra-articular injec-
tion of MSCs for the treatment of focal chondral defects
[29,98]. In a randomized controlled trial, autologous
peripheral blood MSCs were injected with HA weekly
for 5 weeks after subchondral drilling and subsequently
for another 3 weeks at 6 months into the knees of pa-
tients with lesions of the femoral condyle, tibial plateau,
patella, and femoral trochlea. Histologic assessment at
18 months showed the presence of hyaline-like cartilage
in patients who received MSCs. Furthermore, ICRS II
histologic scores were significantly better in participants
who received MSCs and HA versus those who received
HA. However, International Knee Documentation Com-
mittee (IKDC) clinical scores were equivalent between
these two groups at 24 months.
Optimizing technique in mesenchymal stem cell
transplantation
The goal of MSC transplantation is to create repair tissue
with properties of hyaline cartilage that integrates into
surrounding native osteochondral tissue while limiting
Table 3 Current mesenchymal stem cell transplantation protocols
Construct Transplantation protocol Advantages Disadvantages
BMDC-seeded scaffold
[75,80,81,89-91]
Bone marrow aspiration, separation of
nucleated cell population (BMDCs) by
centrifugation, scaffold seeding, and
implantation of BMDC-scaffold
construct into the AC defect site
Accessory cells/GFs create a natural
microenvironment
Low number of MSCs
One step procedure with aspiration
and implantation in the same surgery





Bone marrow aspiration, in vitro MSC
isolation by adherence to plastic flasks,
in vitro expansion of MSCs, scaffold
seeding with MSCs, and implantation
of MSC-scaffold construct into the AC
defect site
High MSC numbers are available due
to expansion
In vitro expansion may increase the risk
of contamination
Isolation allows for purification of
MSCs and potentially reduced
likelihood of rejection in allogeneic
transplant
MSCs have the capacity to become
bone without in vitro cueing prior to






Bone marrow aspiration, MSC isolation
by adherence to plastic flasks,
expansion of MSCs in vitro, scaffold
seeding with MSCs, in vitro
precultivation in medium promoting
chondrogenesis, and implantation of a
cartilage tissue construct into the AC
defect site
High MSC numbers are available due
to expansion
In vitro expansion and cultivation may
increase the risk of contamination
Chondrogenesis is stimulated Highest time and resource
consumption
Increased mechanical stability of the
implanted construct
No clinical assessment to date
Early neo-tissue remodeling occurs
in vitro and may be accounted for at
the time of implantation
AC, articular cartilage; BMDC, bone marrow-derived cell; GF, growth factor; MSC, mesenchymal stem cell.
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transplantation protocols currently exist (Figure 2). The
one-step BMDC transplantation protocol consists of bone
marrow aspiration, separation of a nucleated cell popula-
tion containing MSCs amongst other cells, seeding of
these cells on a scaffold, and implantation all within a
single operative period [80,81,89-91]. A second protocol
involves isolation of MSCs within the laboratory, in vitro
expansion, and scaffold seeding shortly before implant-
ation [82-85,88]. The scaffold may be seeded at the time
of implantation or within a few days after a short in vitro
culture period to promote MSC adherence to the bioma-
terial [82]. The final protocol utilizes isolated, expanded
MSCs that are seeded onto a scaffold and precultivated -
or pre-differentiated - in vitro over 2 to 3 weeks to pro-
mote chondrogenesis prior to implantation [38,66,72].
BMDC transplantation and non-precultivated, isolated
and expanded MSC transplantation have both resulted
in the creation of hyaline-like cartilage based on arthros-
copy, histology and imaging, and yielded positive outcomes
in clinical studies [80,82-85,88-91]. To our knowledge, im-
plantation of precultivated MSC-matrix constructs has not
been studied clinically to date, but was shown to pro-
duce hyaline-like cartilage tissue in large animal in vivo
studies [38,66,72]. Although successful resurfacing has
been performed with all three transplantation protocols,
each carries specific advantages and disadvantages that
are described in Table 3.
At present, studies comparing these protocols in humans
are lacking, but have been performed in animal models.Zhang and colleagues [75] found no difference at 2 months
between BMDCs and expanded MSCs seeded on collagen
gels implanted within femoral trochlea chondral defects in
mini-pigs. Marquass et al. [38,72] showed that preculti-
vated MSC-seeded collagen gels produced superior repair
tissue after 1 year compared with non-precultivated MSCs
within distal femur osteochondral defects in sheep.
Regardless of the specific transplantation protocol used,
MSC-based therapies require a number of steps that may
be optimized to improve MSC yield, chondrogenesis, re-
pair tissue integration, and ultimately clinical outcome.
These steps may include cell collection, MSC isolation
and expansion, matrix seeding, precultivation into cartil-
age tissue, and surgical implantation.
Collection of mesenchymal stem cell-containing tissue
MSCs are present within a number of tissues that may
serve as potential harvest sites (Table 4). To date, needle
aspiration of pelvic bone marrow has been the method
of choice for MSC-based treatment of human AC de-
fects [80,81,83-85,87-91,99]. The use of peripheral blood
MSCs has also been reported clinically [29,98]. Synovial,
periosteal and adipose tissues are other sources that
have been assessed in vivo in the animal literature with
relevance [7,53,70]. Synovial MSCs appear to have im-
proved chondrogenic capacity relative to MSCs from
bone marrow and periosteum based on in vitro assess-
ment [28], although this advantage has not been repro-
duced in vivo in two rabbit studies [53,56]. Adipose tissue
offers the advantage of abundant availability, but adipose
Figure 2 Mesenchymal stem cell transplantation constructs and protocols. (A) In bone marrow-derived cell (BMDC) transplantation, the
bone marrow aspirate is centrifuged to create a BMDC concentrate that contains mesenchymal stem cells (MSCs) within a pool of other cells and
chemical mediators. BMDCs are then seeded onto a scaffold and implanted within a cartilage defect. (B,C) MSC transplantation involves isolating
MSCs from a bone marrow aspirate by plastic adherence and expansion in plastic tissue culture flasks. MSCs are then seeded onto a scaffold and
implanted (B) or precultivated in vitro to promote chondrogenesis prior to implantation (C).
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from bone marrow, synovium and periosteum [28]. Bone
marrow- and periosteum-derived MSCs have a height-
ened osteogenic potential [28]. Although this may be
not ideal for cartilage engineering, it could be advanta-
geous in osseous regeneration within osteochondral le-
sions. While present-day techniques utilize autologousTable 4 Clinically relevant sources of mesenchymal stem cells
MSC source In vivo assessment of focal AC defect
treatment
Advan






Peripheral blood Clinical and pre-clinical [29,61,98] Ease o
Synovial tissue Pre-clinical [50,52-54,56,62,64,67,70] Greate
based
Periosteum Pre-clinical [7,56] Equiva
bone m
Adipose tissue Pre-clinical [46,49,56] Abund
Widesp
AC, articular cartilage; MSC, mesenchymal stem cell.MSCs in transplantation, MSC tissue banking and allo-
geneic transplantation could one day provide an alter-
native strategy [100]. However, further investigation is
required to support allogeneic use of MSCs due to re-
cent work suggesting that both undifferentiated and
chondrogenic-differentiated MSCs cause immunoreac-




Propensity to form osseous tissue
(could be beneficial for osseous
regeneration in osteochondral lesions)
f collection by needle
erm safety reported
f collection by needle Paucity of literature comparing this
source to others
st chondrogenic capacity noted
on in vitro study
Clinical assessment is lacking
lent chondrogenic capacity to
arrow
Propensity to form osseous tissue
Clinical assessment is lacking
ance of tissue Reduced chondrogenic capacity
read anatomic availability Clinical assessment is lacking
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Following bone marrow collection, tissue is placed in
serum-containing medium within plastic culture flasks
and incubated for a number of days [26]. Mononucle-
ated cells, some of which are MSCs, may be quantified
and plated at 10,000 cells per cm2 [84]. MSC isolation
occurs through adherence of MSCs to plastic, as other
cell types are non-adherent and discarded when culture
medium is changed. Cell replication is monitored through
the level of confluence observed by microscopy. Once
confluence is achieved, trypsin and EDTA are used to dis-
rupt adherence, and MSCs are re-plated within a larger
number of flasks [30]. This process is repeated through
multiple passages to allow for expansion to occur. Al-
though a greater number of passages yields a larger num-
ber of total MSCs available for implantation, proliferation
and chondrogenic differentiation potential decrease and
may be lost if cells are expanded through too many pas-
sages [102,103]. These cells are then destined to undergo
osteogenesis [104]. As a result, MSCs are usually ex-
panded through a maximum of two to three passages.
Given that the ratio of MSCs to other cells within the
bone marrow is estimated at one in 10,000 cells, expan-
sion is beneficial and must be optimized to ensure that an
adequate yield of pure MSCs is available for implantation
[105]. Basic fibroblast growth factor (FGF-2 or bFGF)
within culture medium increases MSC growth rate and
maintains multipotency [106]. Furthermore, FGF-2 has
been shown to increase collagen and proteoglycan gene
expression and GAG production [107,108]. Hypoxia dur-
ing MSC expansion also augments chondrogenic potential
[109]. GAG synthesis and gene expression of collagen II
and Sry-related HMG box (SOX)9 significantly increased
in MSC pellet cultures expanded under 3% O2 compared
with those expanded under 21% O2 [109]. Bioreactors
may also be used to improve yield; these provide efficient
nutrient exchange and allow for increased cell densities
during expansion [105].
Biomaterial matrix selection and seeding
Biomaterial matrices provide a framework for MSC pro-
liferation and differentiation, and consolidate MSCs into
three-dimensional structures capable of filling defects.
The vast majority of pre-clinical and clinical studies to
date have used matrices. Gels or pastes composed of col-
lagen or platelet-rich fibrin are moldable substances that
hold the cells suspended [80,82]. Porous scaffolds made
of materials such as collagen and HA serve as malleable,
foam-like structures that adhere MSCs at the time of
seeding [66,82]. Cell-seeded scaffolds with multiple layers
engineered for osteochondral lesions have shown positive
results in animal studies [47]. A tri-layer scaffold com-
posed of collagen and hydroxyapatite has been tested in
humans, but was used as a cell-free scaffold without co-implantation of MSCs [110]. There is potential for use of
this product in conjunction with MSCs in the future.
Combinations of MSC-embedded gels and scaffolds have
been used in some in vivo studies [80,87,91,95].
MSC seeding density has not been routinely reported
to date in clinical studies. One reason for this is that
some trials have used BMDCs, only a few of which are
MSCs, rather than pure isolated MSCs [92]. In the in vivo
animal literature, MSC densities of 10 to 48 million cells
per cm3 of scaffold have been used [45,47,66]. The optimal
number of MSCs to be seeded per unit volume is cur-
rently unknown.
Cell-seeded biomaterial matrix implantation and
reinforcement
Standard open or arthroscopic surgical approaches to the
knee or ankle are used to access chondral and osteochon-
dral defects during implantation procedures [80,82,92,96].
Damaged AC is debrided down to subchondral bone and
the edges are trimmed until a rim of healthy AC is evident
[82,84,93]. In the setting of full-thickness chondral defects,
drilling of intact subchondral bone has been used by some
groups in an attempt to stimulate the influx of cells and
mediators into the repair zone [83,86-88,95], while other
groups have left subchondral bone intact [82,93,111]. Sub-
chondral bone is already disrupted in osteochondral le-
sions. Therefore, careful debridement of malacic bone
may be performed until healthy bone is reached [80].
At the time of implantation, matrices or cell-matrix
constructs may be resized with punches or scalpels to fit
within the margins of the defect [80]. Implantation orien-
tation may be relevant in scaffolds engineered with separ-
ate porous and non-porous sides [45,95].
Fibrin glue or autologous platelet-rich fibrin gel may be
deposited within the defect and overlying the MSC-matrix
construct to augment implant fixation [45,83,84,92]. Su-
tures may be used to anchor cell-seeded scaffolds to
surrounding native cartilage [111]. Autologous periosteal
flaps or biomaterial membranes have also been used to
prevent leakage of MSCs from cell collections implanted
alone [84,93] or embedded within collagen or fibrin gel
[82,83,86,87,95]. Periosteal flaps have been shown to form
superficial fibrous caps that cover hyaline cartilage repair
tissue [82]. In general, they are not recommended for use
in scaffold-associated cell-based therapies, but may be
used to contain implanted MSCs within defect areas when
scaffolds are not used [84].
In vitro precultivation of bioengineered tissue
Various in vitro culture techniques have been elucidated
that may be used to promote the creation of hyaline cartil-
age within precultivated MSC-scaffold constructs. Chem-
ical mediators such as TGF-β and dexamethasone are
placed with culture media for chondrogenic induction [30].
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(BMP-2, −4 and −6) and insulin-like growth factor (IGF)-1
may be used in addition to TGF-β and dexamethasone to
amplify chondrogenesis [42,112]. Ascorbic acid serves as a
cofactor in the hydroxylation of amino acids in collagen,
and is also routinely used within chondrogenic culture
medium [113].
Incubator oxygen tension during precultivation may
be used to modulate chondrogenesis. Hypoxic exposure
was found to increase ECM deposition on scaffolds and
gene expression of collagen II, aggrecan and Sox9 in pellet
cultures [114]. Co-culture of MSCs with chondrocytes
promotes the creation of cartilage through chondrocyte-
enhanced MSC chondrogenesis [115]. Pellet co-culture of
human MSCs and chondrocytes increased GAG depos-
ition and expression of type II collagen while enhancing
MSC-induced chondrocyte proliferation [115]. Cartilage
formation may be augmented by mechanical stimulation
during cultivation through either hydrostatic pressure
or ultrasound. Hydrostatic pressure in constant and cyc-
lic forms increased sulfated GAG matrix deposition by
chondrocytes cultured on collagen scaffolds [116]. Fur-
thermore, low-intensity ultrasound improved histological
chondrogenic morphology, GAG and collagen II content,
as well as gene expression of type II collagen, aggrecan
and SOX9 [37,117].
Bone marrow-derived MSCs have the propensity to
enter an osteogenic pathway, a property that is not ideal
for AC engineering [104]. During precultivation, osteo-
genesis may be dampened using a variety of methods.
Parathyroid hormone-related protein has been shown to
reduce collagen X gene expression and alkaline phosphat-
ase activity [118]. Hypoxic culture of MSCs significantly
suppressed expression of collagen X relative to normoxic
culture [109]. Lastly, co-culture of MSCs with chondro-
cytes reduced osteogenesis based on osteocalcin quantifi-
cation, and Von Kossa and Alizarin Red staining [119].
Discussion: current recommendations and future
directions
MSC-based therapy through injection or implantation is
a promising treatment for traumatic chondral and osteo-
chondral defects. MSC injection offers the advantage of
minimal invasiveness, but dispersion of injected MSCs and
lack of focus of these cells into defects make this method
less appealing than direct implantation techniques. Several
pre-clinical studies have been performed, but only one
group has assessed MSC injection clinically to date [29].
The current literature supports performing microfracture
or subchondral drilling in conjunction with weekly injec-
tions of MSCs and HA over the course of multiple weeks
[29,69,78]. This protocol presumably increases the likeli-
hood of defect seeding with MSCs from both injection and
subchondral marrow sources.MSCs may be implanted alone or in conjunction with
a biomaterial matrix. MSCs implanted and covered with
a periosteal flap in a procedure analogous to ACI pro-
duced good outcomes based on one clinical study [84].
The majority of the current clinical and pre-clinical litera-
ture has focused on matrix-associated transplantation of
MSCs. Three general construct types have been im-
planted, including biomaterial scaffolds seeded with either
BMDCs [80] or isolated and expanded MSCs [82], and
precultivated constructs derived from MSCs cultured
in vitro on scaffolds prior to implantation [38]. All three
protocols are capable of resurfacing focal AC defects with
hyaline-like cartilage that integrates with surrounding
tissue [38,82,89], while each has unique advantages and
disadvantages. At present, all may be considered as poten-
tial treatment options. BMDC-scaffold implantation and
non-precultivated isolated, expanded MSC-scaffold im-
plantation have led to positive functional, arthroscopic,
histologic and radiographic outcomes at 12 to 48 months
in patients with traumatic, focal chondral and osteo-
chondral defects of the knee and ankle [80-84,88,89].
No clinical studies have compared these two protocols,
although one preclinical study found equivalent histo-
logic outcomes [75]. The third protocol, precultivated
MSC-scaffold construct implantation, has only been in-
vestigated in pre-clinical models but should be consid-
ered for clinical implementation given that it produced
superior repair tissue in comparison to non-precultivated
MSC-scaffold constructs over 6 to 12 months in two
sheep studies [38,72].
It is currently unclear whether defect characteristics
should dictate the transplantation protocol used. Both
full-thickness chondral and osteochondral defects have
been treated successfully with the current modalities, but
several important differences exist between these defect
types. In the setting of full-thickness chondral lesions, the
subchondral bone is intact and there is no diffusion of
subchondral marrow contents (MSCs, accessory cells and
growth factors) into the defect site. Some groups have
therefore recommended bone marrow stimulation tech-
niques, such as microfracture and subchondral drilling, to
be performed as an adjunct to MSC/BMDC-scaffold im-
plantation [88,99]. However, other groups have not used
these techniques [80,81,84,90,91], possibly because the re-
pair tissue derived from microfracture or subchondral
drilling may produce fibrocartilage that is mechanically in-
ferior to hyaline cartilage [9]. However, histologic assess-
ment following combined arthroscopic microfracture and
BMDC transplantation - described as the covered micro-
fracture and bone marrow concentrate technique by
Gigante and colleagues [86,87] - showed the presence of
hyaline-like cartilage tissue.
Osteochondral defects are deeper defects that involve
subchondral plate disruption and diffusion of subchondral
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quire more complex regeneration of separate layers of car-
tilage and bone. Tissue consistent with hyaline cartilage
has been found following MSC transplantation [80,81,91].
Subchondral bone regeneration has also been reported,
but restoration requires an extended period of time rela-
tive to cartilage. Specifically, 29 months following treat-
ment of femoral condyle osteochondral defects, Buda and
colleagues [81] noted cartilage surface intactness in 70%,
iso-intense cartilage tissue in 65%, but subchondral lamina
and bone intactness in only 30% of participants on MRI.
Similarly, at 24 months following treatment of talus osteo-
chondral defects, Giannini and colleagues [91] reported
cartilage surface intactness in 40%, iso-intense cartilage
tissue in 70%, but subchondral lamina and bone intactness
in only 10% and 35%, respectively.
Detailed comparisons between MSC transplantation
and other modalities of treatment for traumatic AC de-
fects are lacking in the current literature. Chondrocyte
transplantation (ACI/MACI), the current gold standard of
cell-based treatment, has shown positive outcomes up to
10 to 20 years [20], while MSC/BMDC transplantation
has only been assessed for up to 2 to 4 years. In our re-
view, one pre-clinical large animal study and two clinical
studies were found that directly compared MSC trans-
plantation to chondrocyte transplantation [72,84,90].
Marquass and colleagues [72] reported superior histo-
logic findings in repair tissue derived from precultivated
MSCs in comparison to chondrocytes at 1 year post-
implantation in sheep. Clinically, Nejadnik and colleagues
[84] found similar positive functional outcomes on IKDC,
Tegner and Lysholm scales between MSC implantation
and ACI in the treatment of knee defects, but noted sig-
nificantly higher physical role functioning on the ICRS
Package SF-36 in patients treated with MSCs. Giannini
and colleagues reported similarly improved AOFAS scores
with both MSC and chondrocyte transplantation following
treatment of talus defects [90]. Further comparative evalu-
ation is required to better assess MSC transplantation
relative to chondrocyte implantation.
MSC transplantation may reduce the likelihood of low
chondrocyte yield and chondrocyte de-differentiation as-
sociated with chondrocyte transplantation [23,25,103].
Chondrocyte senescence is a concern with ACI/MACI
[24,120,121], and, although MSCs also undergo senes-
cence over prolonged periods of proliferation, adequate
MSC yields for transplantation may be attained at a
stage during which there is still significant residual pro-
liferative capacity [104]. Chondrocyte transplantation
requires two invasive surgical procedures, one for cell
collection and one for implantation [20]. In contrast,
MSC transplantation only requires one surgical proced-
ure at the time of implantation [88]. MSC collection
may be performed through minimally invasive needleaspiration [82]. Consequently, MSC transplantation may
be less expensive than ACI/MACI. Giannini and col-
leagues [90] found that the total cost of arthroscopic
matrix-associated BMDC transplantation was half of the
cost of arthroscopic MACI and one-third of the cost of
open ACI.
Several technical steps may be optimized in MSC trans-
plantation to promote cell numbers, chondrogenesis, re-
pair tissue integration, and clinical outcome. With respect
to cell collection, autologous bone marrow has been used
in all clinical studies to date and is the current preference
[80-85,88-91]. However, synovial MSCs appear to have su-
perior chondrogenic capacity and should be considered
[28]. Furthermore, adipose tissue is abundantly available
[49]. In MSC isolation, plastic adherence is used [30].
Expansion may be augmented using serum-containing
medium supplemented with FGF-2 and incubation under
hypoxic conditions [106,109]. Several matrix types are
appropriate for MSC transplantation. At present, three-
dimensional scaffolds composed of collagen or hyaluronic
acid are the standard [81,82]. Scaffolds composed of
multiple layers are an option in the setting of osteochon-
dral lesions [47]. Precultivation of MSC-scaffold constructs
should be performed in serum-free medium containing
TGF-β and dexamethasone supplemented with other me-
diators such as ascorbic acid, IGF-1 or BMPs [30,42,112].
Hypoxic incubation, co-culture with chondrocytes, mech-
anical stimulation with ultrasound, and dynamic culture
within a bioreactor are other precultivation optimizing
techniques that should be considered [37,105,109,115]. Im-
plantation may be performed through either open or
arthroscopic techniques. Fibrin glue or autologous platelet-
rich fibrin gel may be used to stabilize implanted con-
structs [83,85]. At present, there is insufficient evidence to
support the use of marrow stimulation (that is, subchon-
dral drilling or microfracture) or periosteal flaps in MSC
transplantation.Conclusion
MSC transplantation is a promising cell-based strategy
for the treatment of traumatic chondral and osteochon-
dral defects of the knee and ankle. Although there is
currently no established consensus protocol, multiple
technical variations have successfully produced hyaline-
like cartilage repair tissue that integrates within native
tissue. Duplication and optimization of current protocols
are important to improve the cartilage ECM formed in a
reliable and safe manner. Clinical studies to date report
positive outcomes at 12 to 48 months following MSC
implantation. Future investigation will provide insight
into long-term outcomes relative to other treatment mo-
dalities and clarify whether MSC transplantation may re-
place present-day techniques as the gold standard.
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